Skip to main content

Table 3 Relative risks of recurrence and death according to clinicopathological parameters and RBM3 expression

From: Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study

   Relative risk of recurrence   Relative risk of death
   Univariate Multivariate   Univariate Multivariate
  n(events) RR(95%CI RR(95%CI n(events) RR(95%CI) RR(95%CI)
Age       
Continuous 255(47) 1.01(0.97-1.05)   255(53) 1.09(1.04-1.13) 1.07(1.02-1.12)
Gender       
Female 132(21) 1.00   132(18) 1.00 1.00
Male 123(26) 1.51(0.85-2.69)    2.60(1.47-4.61) 2.37(1.22-4.57)
Clark level       
II 93(5) 1.00 1.00 93(13) 1.00  
III 103(21) 4.39(1.65-11.65) 1.93(0.51-7.26) 103(21) 1.70(0.85-3.40)  
IV-V 51(21) 9.99(3.76-26.55) 1.02(0.24-4.34) 51(18) 3.04(1.49-6.22)  
Breslow       
Continuous 248(47) 1.07(1.03-1.11)   248(53) 1.07(1.03-1.12)  
Subtype       
SSM, LMM, Other 195(22) 1.00   195(30) 1.00 1.00
Nodular 53(24) 5.63(3.15-10.08)   53(22) 3.86(2.21-6.74) 2.32(1.20-4.94)
Ulceration       
No 213(30) 1.00   214(35) 1.00 1.00
Yes 35(16) 5.80(3.12-10.77)   35(17) 6.29(3.46-11.45) 3.52(1.63-7.61)
Lymphocytic       
infiltrate       
0-1 72(20) 1.00   72(22) 1.00 1.00
2-3 176(76) 0.43(0.24-0.78)   176(30) 0.46(0.26-0.79) 0.55(0.30-1.00)
Clinical stage       
I 179(12) 1.00 1.00 179(22) 1.00  
II-IV 28(13) 15.02(6.39-35.30) 7.36(2.47-21.47) 28(11) 6.48(3.05-13.73)  
Mitotic count       
< 1/mm2 131(7) 1.00 1.00 131(17) 1.00  
> = 1/mm2 122(40) 7.99(3.56-17.80) 2.86(0.96-8.47) 122(36) 1.26(1.19-1.34)  
Vascular invasion       
No 232(35) 1.00 1.00 232(42) 1.00 1.00
Yes 14(11) 9.25(4.67-18.35) 3.40(1.60-7.20) 14(9) 4.88(2.37-10.08) 3.81(1.62-8.97)
RBM3 intensity       
0-2 95(24) 1.00 1.00 95(29) 1.00 1.00
3 120(20) 0.50 (0.27-0.91) 0.87(0.46-1.66) 120(20) 0.36(0.20-0.64) 0.33(0.18-0.61)
  1. The number of cases in the multivariate analysis is equal to the number of cases evaluated for RBM3 expression (n = 215).